Dr. Freeman on Challenges in Treatment Selection in Melanoma

Morganna Freeman, DO
Published: Tuesday, Feb 14, 2017



Morganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.

As with many other cancer types, treatment selection is increasingly difficult as new agents and combinations rapidly emerge in the oncology landscape.

According to Freeman, looking at other tumor types is helpful in determining what therapies might be effective in melanoma. Specifically, PD-L1 as a biomarker has shown promise in lung cancer—and although it is not effective as a biomarker in melanoma—researchers found that patients who are low PD-L1 expressers are more likely to benefit from some sort of combination therapy.
 


Morganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.

As with many other cancer types, treatment selection is increasingly difficult as new agents and combinations rapidly emerge in the oncology landscape.

According to Freeman, looking at other tumor types is helpful in determining what therapies might be effective in melanoma. Specifically, PD-L1 as a biomarker has shown promise in lung cancer—and although it is not effective as a biomarker in melanoma—researchers found that patients who are low PD-L1 expressers are more likely to benefit from some sort of combination therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x